Abstract
There is an unmet clinical need to treat especially bilateral limbal stem cell deficiency (LSCD). For this allogeneic source of limbal stem cells (LSCs) differentiated from human pluripotent stem cells (hPSC) could provide a solution. In our studies, we have developed efficient methods to produce an enriched population of ABCG2‐positive as well as later arising p63/ABCB5‐postive hiPSC‐LSCs and our current research hypothesis is that these cells including both quiescent and proliferative sub‐populations could represent high regenerative potential in future clinical applications. Towards that end, we have been conducting molecular and functional analyses of these different sub‐populations to increase the understanding of their identity and heterogeneity as comparison to native human corneal limbus. With this approach we wish to gather data‐driven strategy towards clinical applications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
